WILMINGTON, Del., July 24,
2024 /PRNewswire-PRWeb/ -- SPI Pharma introduces
Valens™ as a new portfolio brand name grouping product offerings
positioned to serve the vaccine, parenteral dosage form, and
biologic drug market spaces.
SPI's Valens™ brand will initially group together SPI Pharma's
unique products for vaccine adjuvants and will be used to brand
strategic additions to the portfolio focused on developing a full
offering of parenteral excipients, vaccine ingredients, and
materials to support the fast-growing biologics drug excipients
market.
SPI has been a market leader in alum vaccine adjuvants for
decades and has entered into a strategic partnership with Q-Vant
Biosciences to add sustainable saponin adjuvants to the portfolio.
SPI also recently agreed to enter a strategic collaboration with
Inimmune Corp. to develop and commercialize advanced adjuvant
systems. SPI's business development group is currently exploring
several materials and pursuing potential partnerships to further
enhance the portfolio.
Valens will differentiate the high-value biologic, parenteral,
and vaccine ingredients from the rest of SPI Pharma's
pharmaceutical and consumer health product offerings.
"Strong, vigorous, and healthy are common definitions of the
Latin word Valens, and these clearly represent our Valens™
portfolio of adjuvants and parenteral products. Created to enhance
life-saving vaccines and therapies, our Valens™ portfolio supports
SPI Pharma's core value of making a difference. Our goal is to
provide global access to these innovative and synergistic
products," said John McInerney.
About SPI Pharma, Inc.
SPI Pharma, headquartered in Wilmington, Delaware, USA, provides innovative
solutions to global pharmaceutical and consumer health customers.
Product lines include Vaccine Adjuvants, Antacid Actives, Drug
Delivery Systems, High-Performance Excipients, and Taste-Masking
technology. SPI Pharma specializes in drug development services,
having participated in over 60 commercially launched and marketed
drugs globally. With its sites in the
United States, France, and
India, the company solves the most
challenging formulation problems – efficiently, cost-effectively,
and with a focus on service.
Media Contact
William McCarthy, SPI Pharma, 1
800-789-9755, Salesinfo@spipharma.com, www.spipharma.com
View original content to download
multimedia:https://www.prweb.com/releases/spi-pharma-introduces-valens-brand-to-support-strategic-product-expansions-focused-on-parenteral-dose-forms-vaccine-ingredients-adjuvants-and-adjuvant-systems-302205901.html
SOURCE SPI Pharma